In separate, live virtual events, Jonathan L. Kaufman, MD, and Morie A. Gertz, MD, MACP, discussed concerns about using chimeric antigen receptor T-cell therapy for a patient with relapsed/refractory multiple myeloma who is experiencing rapid disease progression.
During a Targeted Oncology™ Case-Based Roundtable™ event, Amit Singal, MD, discussed next steps after diagnosing a patient with metastatic hepatocellular carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed the data supporting the safety and efficacy of loncastuximab tesirine in patients with diffuse large B-cell lymphoma. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sajeve S. Thomas, MD, discussed key trials of immunotherapy in terms of safety and efficacy for patients with metastatic melanoma.
In part 1 of a 2-part series, Hans Hammers, MD, PhD, discusses the current landscape for treating patients with advanced renal cell carcinoma who have had 1 or 2 prior therapies and how tivozanib fits into current treatment practices.
During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth M. Wulff-Burchfield, MD, and participants discussed the choice of frontline options for a patient with favorable-risk clear cell renal cell carcinoma, and how liver or lung metastases affect the decision.
During a Targeted Oncology™ Case-Based Roundtable™ event, Binod Dhakal, MD, MS, and participants discussed which treatment should come next for a patient with relapsed multiple myeloma depending on the patient's ability to travel for care.
During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, discussed data supporting the use of sacituzumab govitecan in advanced urothelial carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Christopher G. Azzoli, MD, discussed treatment options appropriate for a patient who received surgical resection for stage IIB lung adenocarcinoma.
On the heels of an ASCO presentation of data from the phase 3 TALAPRO-2 trial, the FDA has granted approval to the study combination for the treatment of a metastatic castration-resistant prostate cancer subgroup.
During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, discussed the choice of therapy for a patient with relapsed/refractory multiple myeloma. This is is the first of 2 articles based on this event.
In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta Kumar Pal, MD, and participants discussed next-line therapy for a patient with advanced clear cell renal cell carcinoma who progressed on axitinib/pembrolizumab and single-agent cabozantinib.
At a live, virtual event held in partnership with Healthcare Research & Analytics®, Alex F. Herrera Jr, MD, discussed the growing influence of chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
In part 1 of a 2-part series, Alfred L. Garfall, MD, leads a discussion in the use of adding daratumumab to triplet therapy for patients with multiple myeloma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed factors influencing their choice of immunotherapy for a patient with BRAF-negative metastatic melanoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.
During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, MS, discussed with participants how risk groups affect their choice of first-line treatment in renal cell carcinoma. This is the first of 2 articles based on this event.
In the second article of this 2-part series, Douglas Sborov, MD, discusses the relevant data that shows the benefit of giving patients with relapsed/refractory multiple myeloma isatuximab as part of a triplet therapy.
During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen J. Schuster, MD, discussed the use of tafasitamab plus lenalidomide in patients with diffuse large B-cell lymphoma including managing adverse events and treating patients after disease progression.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
In the second part of a live discussion on treating patients with myelofibrosis, Jonathan Abbas, MD, led a talk on the impact of ruxolitinib for these patients and where physicians stand with the use of fedratinib.
The FDA has approved the flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.
Douglas Sborov, MD, MS, discusses and compares the many triplet therapies for patients who show disease progression after several lines of therapy in this first article of a 2 part series.
During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed the use of JAK inhibitors for treatment of patients with primary myelofibrosis.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, and participants discussed the therapies listed on the National Comprehensive Cancer Network guidelines for patients with relapse after 1 or more prior lines of therapy. This is the first of 2 articles based on this event.